Drug Profile
Nafamostat
Alternative Names: FUT-175; Futhan; Nafamostat mesilate; Nafamostat mesylateLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Torii Pharmaceutical
- Developer Banyu; Taiho Pharmaceutical; Torii Pharmaceutical
- Class Anti-inflammatories; Anticoagulants; Antivirals; Guanidines; Mucolytics; Small molecules
- Mechanism of Action Peptide hydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Blood coagulation disorders; Disseminated intravascular coagulation; Pancreatitis
- Discontinued Atherosclerosis; Autoimmune disorders; Cancer; Reperfusion injury; Xenotransplant rejection
Most Recent Events
- 24 May 1999 Preclinical development for Atherosclerosis in Japan (Unknown route)
- 24 May 1999 Preclinical development for Coagulation disorders in Sweden (Unknown route)
- 24 May 1999 Preclinical development for Reperfusion injury in Japan (Unknown route)